Clinical Trials
9 trialsNCT03725761 2026-06-04
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT04230109 2026-06-02
NeoSTAR
Massachusetts General Hospital
Phase 2 Recruiting
NCT06963905 2026-05-22
SIMONE
Yale University
Phase 1/2 Recruiting
NCT05675579 2026-05-20
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07011654 2026-05-20
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06204614 2026-05-18
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Enrolling by invitation
NCT06431633 2026-05-18
ARIAN
Fundación GECP
Phase 3 Recruiting
NCT07582887 2026-05-13
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Recruiting
NCT07178730 2026-05-06
ADAPT-TN-IV
West German Study Group
Phase 3 Not yet recruiting